Exp Clin Endocrinol Diabetes 2018; 126(04): 198-204
DOI: 10.1055/s-0043-110480
© Georg Thieme Verlag KG Stuttgart · New York

Impact of Autoimmune Thyroiditis on Reproductive and Metabolic Parameters in Patients with Polycystic Ovary Syndrome

Jan Ulrich
1   Endokrinologikum Hamburg, Lornsenstraße 4-6; Hamburg, Germany
2   Asklepios Klinik St. Georg, Allgemeine Innere Medizin, Lohmühlenstraße 5; Hamburg, Germany
Julia Goerges
1   Endokrinologikum Hamburg, Lornsenstraße 4-6; Hamburg, Germany
3   Amalie Sieveking Hospital, Allgemeine Innere Medizin, Gastroenterologie, Kardiologie, Haselkamp 33; Hamburg, Germany
Christoph Keck
1   Endokrinologikum Hamburg, Lornsenstraße 4-6; Hamburg, Germany
Dirk Müller-Wieland
4   Universitätsklinikum der RWTH Aachen, Medizinische Klinik I, Pauwelstr. 30, Aachen, Germany
Sven Diederich
5   Medicover Berlin, Hausvogteiplatz 3-4, Berlin, Germany
Onno Eilard Janssen
1   Endokrinologikum Hamburg, Lornsenstraße 4-6; Hamburg, Germany
› Author Affiliations
Further Information

Publication History

received 29 January 2017
revised 30 April 2017

accepted 04 May 2017

Publication Date:
05 March 2018 (online)


Background Autoimmune thyroiditis (AIT) has been found to be associated with polycystic ovary syndrome (PCOS). The aim of this retrospective cohort study using data from a fertility clinic, with patients recruited from 2009 to 2010, was to confirm the higher prevalence of AIT in PCOS and to evaluate the impact of AIT on reproductive and metabolic parameters of PCOS patients.

Methods Patients comprised 827 PCOS subjects seen for reproductive or metabolic complaints. Patients presenting primarily for thyroid problems were excluded. All patients were tested for the presence of AIT by laboratory testing and thyroid ultrasound. The impact of AIT on PCOS was evaluated by determination of reproductive and metabolic parameters.

Results Patients with PCOS and AIT as compared to those only with PCOS, had a lower prevalence of elevated testosterone (45 vs. 61%; p=0,0001), free androgen index (5,96±5,41 vs. 7,02±7,6; p<0,001) and hyperandrogenemia (66 vs. 78%; p<0,001). Also testosterone levels were lower in PCOS patients with AIT (0,50±0,30 vs. 0,63±0,71; p=0,0006). Consequently, in these patients, hirsutism was less frequent (51 vs. 66%; p=0,0021). There was no difference in the prevalence of acne, alopecia, a-/ or oligomenorrhea or PCO-morphology in the two patient groups. Patients with PCOS and AIT were more obese by 2 kg/m² BMI on average. A higher BMI correlated with a higher TSH value, although all patients were euthyroid.

Conclusions AIT is more prevalent in PCOS than in controls. PCOS patients with AIT have less severe hyperandrogenemia and hyperandrogenism but are likely to suffer from an elevated metabolic risk.

  • References

  • 1 Legro RS, Arslanian SA, Ehrmann DA. et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-4592
  • 2 Conway G, Dewailly D, Diamanti-Kandarakis E. et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocrinol 2014; 171: 1-29
  • 3 Janssen OE, Hahn S, Tan S. et al. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 45-52
  • 4 Veltman-Verhulst SM, Boivin J, Eijkemans MJ. et al. Emotional distress is a common risk in women with polycystic ovary syndrome: A systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18: 638-651
  • 5 Tan S, Bechmann LP, Benson S. et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-348
  • 6 Wehr E, Möller R, Horejsi R. et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr 2009; 121: 262-269
  • 7 Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: Phenotype and adiposity impact. Trends Endocrinol Metab 2015; 26: 136-143
  • 8 Shaw LJ, Bairey Merz CN, Azziz R. et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health–National heart, lung, and blood institute sponsored women's ischemia syndrome evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284
  • 9 Janssen OE, Mehlmauer N, Hahn S. et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004; 150: 363-369
  • 10 Wu X, Zhang Z, Su Y. Functional states of pituitary-ovary, adrenal and thyroid axes in women with polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi 1998; 33: 153-156
  • 11 Du D, Li X. The relationship between thyroiditis and polycystic ovary syndrome: A meta-analysis. Int J. Clin Exp Med 2013; 6: 880-889
  • 12 Gaberšček S, Zaletel K, Schwetz V. et al. Mechanisms in endocrinology: Thyroid and polycystic ovary syndrome. Eur J Endocrinol 2015; 172: R9-21
  • 13 Singla R, Gupta Y, Khemani M. et al. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrin Metab 2015; 19: 25-29
  • 14 Führer D, Mann K, Feldkamp J. et al Schilddrüsenfunktionsstörungen in der Schwangerschaft. Dtsch Med Wochenschr 2014; 139: 2148-2152
  • 15 Brenta G, Vaisman M, Sgarbi JA. et al. Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS). Clinical practice guidelines for the management of hypothyroidism. Arc Bras Endocrinol Metabol 2013; 57: 265-291
  • 16 Garber JR, Cobin RH, Gharib H. et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on hypothyroidism in adults. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22: 1200-1235
  • 17 Lazarus J, Brown RS, Daumerie C. et al. European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J 2014; 3: 76-94
  • 18 Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocrin Rev 2010; 31: 702-755
  • 19 Day FR, Hinds DA, Tung JY. et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun 2015; 6: 8464
  • 20 Hayes MG, Urbanek M, Ehrmann DA. et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6: 7502
  • 21 Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmun Rev 2014; 13: 391-397
  • 22 Dumesic DA, Oberfield SE, Stener-Victorin E. et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrin Rev 2015; 36: 487-525
  • 23 González F. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin Reprod Med 2015; 33: 276-286
  • 24 Muscogiuri G, Palomba S, Caggiano M. et al. Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. Endocrine 2016; 53: 538-542
  • 25 Calvar CE, Bengolea SV, Deutsch S. et al. Alta Frecuencia de trastornos tiroideos en el sindrome de ovario poliquistico [High frequency of thyroid abnormalities in polycystic ovary syndrome]. Medicina (B Aires) 2015; 75: 213-217
  • 26 Ganie MA, Marwaha RK, Aggarwal R. et al. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: A case-control study. Eur J Endocrinol 2010; 162: 1117-1122
  • 27 Kachuei M, Jafari F, Kachuei A. et al. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2012; 285: 853-856
  • 28 Celik C, Abali R, Tasdemir N. et al. Is subclinical hypothyroidism contributing dyslipidemia and insulin resistance in women with polycystic ovary syndrome?. Gynecol Endocrinol 2012; 28: 615-618
  • 29 Garelli S, Masiero S, Plebani M. et al. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 169: 248-251
  • 30 Salehpour S, Saharkhiz N, Moeini A. et al. Antithyroid peroxidase antibodies in women with polycystic ovary syndrome. Iran J Reprod Med 2013; 11: 1031-1032
  • 31 Enzevaei A, Salehpour S, Tohidi M. et al. Subclinical hypothyroidism and insulin resistance in polycystic ovary syndrome: Is there a relationship?. Iran J Reprod Med 2014; 12: 481-486
  • 32 Sinha U, Sinharay K, Saha S. et al. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian J Endocrin Metab 2013; 17: 304-309
  • 33 Ott J, Aust S, Kurz C. et al. Elevated antithyroid peroxidase antibodies indicating Hashimoto’s thyroiditis are associated with the treatment response in infertile women with polycystic ovary syndrome. Fertil Steril 2010; 94: 2895-2897
  • 34 Benetti-Pinto CL, Berini Piccolo VR, Mendes Garmes H. et al. Subclinical hypothyroidism in young women with polycystic ovary syndrome: An analysis of clinical, hormonal, and metabolic parameters. Fertil Steril 2012; 99: 588-592
  • 35 Novais Jde S, Benetti-Pinto CL, Garmes HM. et al. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecol Endocrinol 2015; 31: 48-51
  • 36 Al-Saab R, Haddad S. Detection of thyroid autoimmunity markers in euthyroid women with polycystic ovary syndrome: A case-control study from syria. Int J Endocrinol Metab 2014; 12: e17954
  • 37 Petrikova J, Lazurova I, Dravecka I. et al. The prevalence of non-organ specific and thyroid autoimmunity in patients with polycystic ovary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158: 1-5
  • 38 Glintborg D, Hass Rubin K, Nybo M. et al. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol 2015; 172: 627-638
  • 39 Anaforoglu I, Topbas M, Algun E. Relative associations of polycystic ovarian syndrome vs metabolic syndrome with thyroid function, volume, nodularity and autoimmunity. J Endocrinol Invest 2011; 34: e295-e264
  • 40 Schmidt J, Brännström M, Landin-Wilhelmsen K. et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): A 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 2011; 96: 2178-2185
  • 41 Najem FI, Elmehdawi RR, Swalem AM. Clinical and biochemical characteristics of polycystic ovary syndrome in benghazi- libya; A retrospective study. Libyan J Med 2008; 3: 71-74
  • 42 Petríková J, Lazúrová I, Yehuda S. Polycystic ovary syndrome and autoimmunity. Eur J Intern Med 2010; 21: 369-371
  • 43 Li Q, Yang G, Wang Y. et al. Common genetic variation in the 3'-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients. Hum Genet 2011; 129: 553-561
  • 44 Mueller A, Schöfl C, Dittrich R. et al. Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Hum Reprod 2009; 24: 2924-2930